English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Renal cancer is a pathology that, like other neoplasms, if it is early diagnosed, it can have a better prognosis. The clinical variability is a factor that could affect its diagnosis. Rev. virtual Soc. Parag. Med. Int. marzo 2017; 4 (1):70-76 Doi:10.18004/rvspmi/ 2017.04(01)70-076 2312-3893/ Autor correspondiente: Dr. Fausto Gady Torres Toala Dirección: Vicente Cárdenas E5-78. Quito, Ecuador. Teléfono:+593.995612493 Correo electrónico: gtorres@makroscopio.com Artículo recibido: 16 enero 2017 Artículo aceptado: 23 enero 2017 Objective: To evaluate the knowledge level and the perceptions about metastatic renal cancer of the Ecuadorian clinical oncologists. Methodology: This was cross-sectional study. The information was collected using a survey designed for this research study. Results: The variability in the knowledge of the professionals was low. Their experience in their care practice with complex medicines was wide, specially with sunitinib. The decision of systemic handling of the metastatic cancer was achieved from peers or multidisciplinary groups but always clinical criterion were prioritized over the administrative ones. Conclusions: The oncologists had low variability in their knowledge and wide experience in the use of complex medicines, however, the situation of access to high cost medicines was a factor present in the majority.

Knowledge and perception of Ecuadorian oncologists about handling and access to medicines in mestastatic renal cancer